journal article·2026-06Open access

Lipid Tail Length Determines Nano‐Bio Interactions of Peptide Amphiphile Nanostructures

Karla Bonic, Morgan R. Stewart, Li Xiang, Kailin Mooney, Randall Armstrong, Sadik Esener, Jared M. Fischer, Adem Yildirim

Small· Volume 22· Issue 31

Abstract

ABSTRACT Understanding the interactions of nanomaterials with biological systems is essential to designing effective nanomedicines. However, most of our understanding originates from studies with solid nanoparticles, and nano‐bio interactions of self‐assembled nanomaterials have remained largely unexplored. To address this knowledge gap, we develop a series of self‐assembling peptide amphiphiles (PAs) with different lipid modifications and investigate their interactions with biological systems. We find that PA nanostructures rapidly disassemble and reassemble with albumin and lipoproteins in blood plasma. While PAs with shorter lipid tails mainly assemble with albumin, increasing lipid length shifts binding to lipoproteins. All PAs show strong tumor accumulation in 4T1 tumor‐bearing mice with tumor to liver ratios of ∼3–6. Overall, albumin‐binding improves blood circulation (up to 1.6‐fold) and tumor accumulation (up to 3‐fold) compared to lipoprotein‐binding, but also shows slower healthy tissue clearance. This study shows that the biointeractions of self‐assembled nanomaterials can be controlled through molecular design, which may lead to the development of effective nanomedicines.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Supramolecular Self-Assembly in Materials · Lipid Membrane Structure and Behavior · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CEDAR, Knight Cancer Institute School of Medicine Oregon Health & Science University Portland Oregon USA

Department of Biomedical Engineering School of Medicine Oregon Health & Science University Portland Oregon USA

Division of Oncological Sciences Knight Cancer Institute School of Medicine Oregon Health & Science University Portland Oregon USA

Department of Molecular and Medical Genetics Oregon Health & Science University Portland Oregon USA

Funding

National Science Foundation

References (41)

Show source-provided references
1. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
2. 10.1021/acs.chemrev.5b0011610.1021/acs.chemrev.5b00116 ↗
3. 10.1038/s41568-022-00496-910.1038/s41568-022-00496-9 ↗
4. 10.1016/j.medj.2022.12.00110.1016/j.medj.2022.12.001 ↗
5. 10.3390/biom1206078410.3390/biom12060784 ↗
6. 10.1038/s41392-023-01536-y10.1038/s41392-023-01536-y ↗
7. 10.2217/nnm-2017-003910.2217/nnm-2017-0039 ↗
8. 10.1021/acs.nanolett.0c0463810.1021/acs.nanolett.0c04638 ↗
9. 10.1007/s13346-020-00740-510.1007/s13346-020-00740-5 ↗
10. 10.3390/biom1506080210.3390/biom15060802 ↗
11. 10.3390/pharmaceutics1404072810.3390/pharmaceutics14040728 ↗
12. 10.1016/j.addr.2020.08.00310.1016/j.addr.2020.08.003 ↗
13. 10.1016/j.heliyon.2022.e0957710.1016/j.heliyon.2022.e09577 ↗
14. 10.1016/j.cmet.2015.12.00610.1016/j.cmet.2015.12.006 ↗
15. 10.1002/mco2.2710.1002/mco2.27 ↗
16. 10.1186/1758-5996-3-1110.1186/1758-5996-3-11 ↗
17. 10.3390/pharmaceutics1511262310.3390/pharmaceutics15112623 ↗
18. 10.1016/j.addr.2016.04.02010.1016/j.addr.2016.04.020 ↗
19. 10.1208/s12249-014-0177-910.1208/s12249-014-0177-9 ↗
20. 10.1016/j.addr.2018.07.01110.1016/j.addr.2018.07.011 ↗
21. 10.1021/ar200017e10.1021/ar200017e ↗
22. 10.7150/thno.8800210.7150/thno.88002 ↗
23. 10.1038/s41551-025-01400-010.1038/s41551-025-01400-0 ↗
24. 10.1001/jamaoncol.2015.310110.1001/jamaoncol.2015.3101 ↗
25. 10.1016/j.jconrel.2022.11.03410.1016/j.jconrel.2022.11.034 ↗
26. 10.1002/adma.20250935910.1002/adma.202509359 ↗
27. 10.1021/acs.accounts.7b0029710.1021/acs.accounts.7b00297 ↗
28. 10.3390/life1206078410.3390/life12060784 ↗
29. 10.3389/fonc.2022.80347310.3389/fonc.2022.803473 ↗
30. 10.1016/j.addr.2016.04.03010.1016/j.addr.2016.04.030 ↗
31. 10.1038/s12276-023-01079-w10.1038/s12276-023-01079-w ↗
32. 10.1021/nn304760510.1021/nn3047605 ↗
33. 10.1002/psc.263310.1002/psc.2633 ↗
34. 10.1021/acs.molpharmaceut.1c0004610.1021/acs.molpharmaceut.1c00046 ↗
35. Analysis of Drug Interactions with Lipoproteins by High‐ Performance Affinity Chromatography
36. 10.1211/002235799177207910.1211/0022357991772079 ↗
37. 10.1055/s-0043-12393710.1055/s-0043-123937 ↗
38. 10.7150/ijbs.5.47410.7150/ijbs.5.474 ↗
39. 10.1021/acsnano.5b0752210.1021/acsnano.5b07522 ↗
40. Peters T. · 1996
41. 10.1152/physrev.00049.201010.1152/physrev.00049.2010 ↗